Get this delivered to your inbox, and more info about our products and services.
Danaher is tapping the M&A well yet again. But we might have had enough
Danaher shares fell on the news that it was acquiring medtech player Masimo.
14 words~1 min read
Related reading
Danaher gives investors reasons to stick around, sending beaten-up shares flying
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
Danaher stock may be turning the corner. What needs to happen to keep it that…
Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
Jim Cramer has faith in Danaher's turnaround as life sciences comes back to life
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Danaher stock fails to rise on solid earnings — leading us to question what's…
While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.
Danaher to buy Masimo in $9.9 billion deal in diagnostics push
The companies said on Tuesday that Danaher will pay $180 per share to buy Masimo. The offer represents a premium of 38.3% to…
Why Wall Street and Jim Cramer think Danaher stock is 'ready to go for a romp'
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does, too.